The pursuit of pharmacological enhancement for stroke rehabilitation has encountered another setback, highlighting the complexity of translating promising preclinical findings into clinical benefit. While animal studies have consistently shown that levodopa can enhance motor learning and neuroplasticity after brain injury, human trials continue to produce disappointing results. The ESTREL trial's failure to demonstrate improved motor recovery when adding levodopa to standard rehabilitation represents more than just another negative study—it underscores fundamental questions about how we optimize drug delivery for neurological recovery. The trial used a specific dosing protocol that may not have achieved the sustained dopamine levels necessary to enhance motor learning during rehabilitation sessions. Critics point to pharmacokinetic limitations, noting that levodopa's short half-life and variable absorption could have prevented consistent therapeutic levels during critical training periods. This mirrors broader challenges in stroke pharmacotherapy, where timing, dosing, and individual patient factors create a complex optimization problem. The stroke rehabilitation field has seen similar disappointments with other promising compounds, from growth factors to nootropics, suggesting that the translation gap between laboratory models and human stroke recovery remains substantial. Future trials may need to embrace more personalized approaches, potentially using continuous infusion protocols or combining levodopa with other agents to maintain stable dopamine receptor activation. The persistent interest in dopaminergic enhancement reflects the biological rationale—dopamine pathways are crucial for motor learning and reward-based behaviors that drive rehabilitation engagement. However, these results suggest that simply adding levodopa to existing rehabilitation protocols may be insufficient, and more sophisticated delivery strategies or patient selection criteria may be required to unlock any potential benefits.